Navigation Links
Radient Pharmaceuticals Announces FY 2011 Third Quarter Results
Date:11/14/2011

TUSTIN, Calif., Nov. 14, 2011 /PRNewswire/ -- Radient Pharmaceuticals Corporation (OTCQX:RXPC) (OTCPK:RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced financial results for its third quarter ended September 30, 2011.

Revenues for the third quarter ended September 30, 2011 were $102,238 as compared to $34,446 for the quarter ended September 30, 2010.  For the nine months ended September 30, 2011, revenues were $257,609, as compared to $116,840 for the nine months ended September 30, 2010.  Loss from operations for the three months ended September 30, 2011 was $1,801,713, as compared to $2,338,665 for the three months ended September 30, 2010. The $536,952 (approximately 23%) decrease in our losses from operations was primarily due to an increase in sales combined with a decrease in selling, general and administrative expenses and research and development expenses.

Similarly, loss from operations for the nine months ended September 30, 2011 was $5,620,761, as compared to a loss of $6,705,359 in the nine months ended September 30, 2010.  The $1,084,598 (approximately 16%) decrease in loss from operations was primarily due to an increase in sales combined with a decrease in selling, general and administrative expenses and research and development expenses.

Net income for the three months ended September 30, 2011 was $1,947,075 or a basic and diluted income of $0.01 per common share.  Net income included a gain of $12,312,333 from the change in fair value of derivative instruments.  Net loss for the same period in 2010 was $11,946,784 or a basic and diluted loss of $0.39 per common share.

For the nine months ended September 30, 2011 the net loss was $39,417,159 or a basic and diluted loss of $0.24 per common share, as compared to a net loss of $38,420,688 or a basic and diluted loss per common shares of $1.38.  The increase in net loss is attributed to higher int
'/>"/>

SOURCE Radient Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report
2. Radient Pharmaceuticals Corporation Joins OTCQX
3. Merriman Capital Announces Sponsorship of Radient Pharmaceuticals Corporation on OTCQX
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)...   TRU-D SmartUVC LLC, producers of the ... today that the General Services Administration has awarded the ... This newly formed agreement will allow TRU-D ... purchasers, including Department of Veteran Affairs and Department of ... purchasing solutions for the Ebola effort in ...
(Date:12/22/2014)... Dec. 22, 2014  ConvaTec, a privately-held medical products ... been appointed Interim Chief Executive Officer of the company, ... Ken Berger .  "The Board of Directors of ... ConvaTec over the past three years," said Magnus ... "We are confident that the company is well positioned ...
(Date:12/22/2014)... , Dec. 22, 2014 Swedish Orphan ... today announced that the Committee for Medicinal Products for ... has adopted a positive opinion for the use of ... men with Peyronie,s disease with a palpable plaque and ... start of therapy. The use of Xiapex ...
Breaking Medicine Technology:TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
(Date:12/24/2014)... 24, 2014 The 2014 Market ... professional and in-depth research report on COC industry. ... basic information, including its definition, classification, application, industry ... etc. This report also presents product specification, manufacturing ... separated by regions, technology and applications. Analysis also ...
(Date:12/24/2014)... Plantation, FL (PRWEB) December 24, 2014 ... permanent solution for a tooth replacement. They offer the ... boast several advantages over other forms of tooth replacement. ... not rely on the adjacent teeth for support, and ... many people have been told that they are not ...
(Date:12/24/2014)... Dr. Ronald Receveur, a New Albany ... dental implants in a day, has written a ... teeth-whitening treatments. , In his blog published Dec. ... writes that overusing teeth-whitening treatments can lead to tooth ... , “Because teeth-whitening treatments are available in ...
(Date:12/24/2014)... Dec. 23, 2014 (HealthDay News) -- Longer and colder body ... who have brain damage from a lack of oxygen, a ... in newborns with this condition -- called hypoxic ischemic encephalopathy ... 33.5 degrees Celsius (92.3 Fahrenheit) for 72 hours, experts say. ... the brains of animals, so this study examined if the ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 B. E. ... to healthcare providers, has been retained to lead a ... Tri-City Medical Center in Oceanside, Calif. The top ... B. E. Smith has recently placed more than 900 ... is a community owned, 397-bed, Gold Seal-approved, full-service acute-care ...
Breaking Medicine News(10 mins):Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3Health News:Innovative Dental Implant Procedure to Gain Momentum in the New Year 2Health News:New Albany Dentist Weighs In On New Trend of Overbleaching Teeth 2Health News:New Albany Dentist Weighs In On New Trend of Overbleaching Teeth 3Health News:Greater Cooling of Oxygen-Deprived Infants Fails to Improve Survival 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 3
... new study published in the journal Ultrasound in Obstetrics ... infant survival rate in severe cases of congenital diaphragmatic hernia ... a severe malformation (hole) of the diaphragm and is a ... an incomplete development of the lungs. Researchers led by ...
... FOR DEC. 14, 2011] The two main ways to ... antiviral drugs. A team of investigators has found that ... complement these approaches and reduce mortality among patients hospitalized ... Journal of Infectious Diseases and are now available ...
... Dec. 13 (HealthDay News) -- An older woman,s sleep/wake cycle ... developing dementia, a new study suggests. It found that ... that sometimes precedes dementia) was higher in older women with ... more active later in the day, compared to those who ...
... fluid bathing the brain are linked to poor recovery ... University School of Medicine in St. Louis and the ... "We are particularly interested in finding ways to ... David L. Brody, MD, PhD, assistant professor of neurology ...
... 13, 2011 The American Cancer Society has revised ... consistency, and rigor in creating guidance about cancer ... from the Institutes of Medicine (IOM) by creating ... commissioning systematic evidence reviews, and clearly articulating the ...
... The U.S. Department of Justice filed a proposed consent ... requirements for three major tobacco companies to make internal ... the companies violated the Racketeer Influenced and Corrupt Organizations ... Tobacco Documents Library (LTDL). The order, once approved ...
Cached Medicine News:Health News:Statins may reduce mortality in patients hospitalized with influenza 2Health News:'Body Clock' Might Affect Women's Dementia Risk 2Health News:High levels of tau protein linked to poor recovery after brain injury 2Health News:High levels of tau protein linked to poor recovery after brain injury 3Health News:American Cancer Society revises cancer screening guideline process 2Health News:UCSF to receive tobacco papers, funding to improve public access to the documents 2
The TCM400 is the first and only portable instrument to provide up to six simultaneous measurements of transcutaneous oxygen tension (tcpO2)...
Two separate sensors provide continuous measurement of tcpO2/tcpCO2 and SpO2....
... the only online source of nationally accredited ... care nurses and other healthcare professionals., ,Radiometers ... you can take them at your convenience. ... is issued upon course completion. The curriculum ...
... components that comprise the SmartPill GI ... comprise the SmartPill GI Monitoring System: ... Receiver software and SmartPill MotiliGI software. ... indispensable parts of the SmartPill GI ...
Medicine Products: